Clovis Oncology Inc (CLVS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH189107D
- Pages: 62
- November 2018
- Total Views:1181
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Clovis Oncology Inc (Clovis) is a biopharmaceutical company that acquires, develops and commercializes new anti-cancer agents. The company's development programs are targeted at specific cancer indications, combining personalized medicine with companion diagnostics. It develops and commercializes rights for rociletinib, rucaparib and holds right in the US and Japan for lucitanib. Clovis has collaboration agreements with various companies such as Celgene Avilomics Research Inc.; Advenchen Laboratories LLC; Pfizer Inc. and Les Laboratoires Servier for the development and commercialization of its product candidates. The company operates offices in San Francisco and California, the US; Cambridge, the UK; and Milan, Italy. Clovis is headquartered in Boulder, Colorado, the US.
Clovis Oncology Inc (CLVS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Clovis Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Clovis Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 10
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Clovis Oncology Enters into Agreement with Immunomedics 12
Bristol-Myers Squibb and Clovis Oncology Enter into Agreement 13
Clovis Oncology Enters into Agreement with Strata Oncology 14
Clovis Oncology Enters into Agreement with Genentech 15
Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 16
Licensing Agreements 17
Clovis Oncology Enters into Licensing Agreement with Gatekeeper Pharma 17
Clovis Oncology Enters into Licensing Agreement with AstraZeneca 18
Equity Offering 19
Clovis Oncology Raises USD100 Million in Public Offering of Shares 19
Clovis Oncology Raises USD342.4 Million in Public Offering of Shares 21
Clovis Oncology Raises USD235.75 million in Public Offering Of Shares 23
Clovis Oncology Raises USD316 Million in Public Offering of Shares 25
Clovis Oncology Completes Public Offering Of Shares For USD 262 Million 27
Clovis Oncology Completes Public Offering Of Common Stock For USD 75 Million 29
Debt Offering 31
Clovis Oncology Raises USD300 Million in Public Offering of Notes Due 2025 31
Clovis Oncology Completes Private Placement of Notes Due 2021 for USD287.5 Million 32
Acquisition 33
Clovis Oncology Acquires EOS For USD 420 Million 33
Clovis Oncology Inc-Key Competitors 35
Clovis Oncology Inc-Key Employees 36
Clovis Oncology Inc-Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Oct 30, 2018: Clovis Oncology announces third quarter 2018 operating results 38
Aug 01, 2018: Clovis Oncology announces second quarter 2018 operating results 41
May 08, 2018: Clovis Oncology Reports First Quarter 2018 Operating Results 44
Feb 26, 2018: Clovis Oncology Announces 2017 Financial Results 47
Nov 01, 2017: Clovis Oncology Announces Third Quarter 2017 Operating Results 50
Aug 02, 2017: Clovis Oncology Announces Second Quarter 2017 Operating Results 53
May 03, 2017: Clovis Oncology Announces First Quarter 2017 Operating Results 56
Feb 22, 2017: Clovis Oncology Announces 2016 Operating Results 59
Corporate Communications 61
Oct 11, 2018: Clovis Oncology appoints two new Directors to its Board 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62
List Of Figure
List of Figures
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Clovis Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Clovis Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Clovis Oncology Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Clovis Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 10
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Clovis Oncology Enters into Agreement with Immunomedics 12
Bristol-Myers Squibb and Clovis Oncology Enter into Agreement 13
Clovis Oncology Enters into Agreement with Strata Oncology 14
Clovis Oncology Enters into Agreement with Genentech 15
Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 16
Clovis Oncology Enters into Licensing Agreement with Gatekeeper Pharma 17
Clovis Oncology Enters into Licensing Agreement with AstraZeneca 18
Clovis Oncology Raises USD100 Million in Public Offering of Shares 19
Clovis Oncology Raises USD342.4 Million in Public Offering of Shares 21
Clovis Oncology Raises USD235.75 million in Public Offering Of Shares 23
Clovis Oncology Raises USD316 Million in Public Offering of Shares 25
Clovis Oncology Completes Public Offering Of Shares For USD 262 Million 27
Clovis Oncology Completes Public Offering Of Common Stock For USD 75 Million 29
Clovis Oncology Raises USD300 Million in Public Offering of Notes Due 2025 31
Clovis Oncology Completes Private Placement of Notes Due 2021 for USD287.5 Million 32
Clovis Oncology Acquires EOS For USD 420 Million 33
Clovis Oncology Inc, Key Competitors 35
Clovis Oncology Inc, Key Employees 36
Clovis Oncology Inc, Other Locations 37
Clovis Oncology Inc, Subsidiaries 37
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Clovis Oncology Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Clovis Oncology Inc (Clovis) is a biopharmaceutical company that acquires, develops and commercializes new anti-cancer agents. The company's development programs are targeted at specific cancer indications, combining personalized medicine with companion diagnostics. It develops and commercializes rights for rociletinib, rucaparib and holds right in the US and Japan for lucitanib. Clovis has collaboration agreements with various companies such as Celgene Avilomics Research Inc.; Advenchen Laboratories LLC; Pfizer Inc. and Les Laboratoires Servier for the development and commercialization of its product candidates. The company operates offices in San Francisco and California, the US; Cambridge, the UK; and Milan, Italy. Clovis is headquartered in Boulder, Colorado, the US.
Clovis Oncology Inc (CLVS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Clovis Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Clovis Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 10
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Clovis Oncology Enters into Agreement with Immunomedics 12
Bristol-Myers Squibb and Clovis Oncology Enter into Agreement 13
Clovis Oncology Enters into Agreement with Strata Oncology 14
Clovis Oncology Enters into Agreement with Genentech 15
Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 16
Licensing Agreements 17
Clovis Oncology Enters into Licensing Agreement with Gatekeeper Pharma 17
Clovis Oncology Enters into Licensing Agreement with AstraZeneca 18
Equity Offering 19
Clovis Oncology Raises USD100 Million in Public Offering of Shares 19
Clovis Oncology Raises USD342.4 Million in Public Offering of Shares 21
Clovis Oncology Raises USD235.75 million in Public Offering Of Shares 23
Clovis Oncology Raises USD316 Million in Public Offering of Shares 25
Clovis Oncology Completes Public Offering Of Shares For USD 262 Million 27
Clovis Oncology Completes Public Offering Of Common Stock For USD 75 Million 29
Debt Offering 31
Clovis Oncology Raises USD300 Million in Public Offering of Notes Due 2025 31
Clovis Oncology Completes Private Placement of Notes Due 2021 for USD287.5 Million 32
Acquisition 33
Clovis Oncology Acquires EOS For USD 420 Million 33
Clovis Oncology Inc-Key Competitors 35
Clovis Oncology Inc-Key Employees 36
Clovis Oncology Inc-Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Oct 30, 2018: Clovis Oncology announces third quarter 2018 operating results 38
Aug 01, 2018: Clovis Oncology announces second quarter 2018 operating results 41
May 08, 2018: Clovis Oncology Reports First Quarter 2018 Operating Results 44
Feb 26, 2018: Clovis Oncology Announces 2017 Financial Results 47
Nov 01, 2017: Clovis Oncology Announces Third Quarter 2017 Operating Results 50
Aug 02, 2017: Clovis Oncology Announces Second Quarter 2017 Operating Results 53
May 03, 2017: Clovis Oncology Announces First Quarter 2017 Operating Results 56
Feb 22, 2017: Clovis Oncology Announces 2016 Operating Results 59
Corporate Communications 61
Oct 11, 2018: Clovis Oncology appoints two new Directors to its Board 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62
List Of Figure
List of Figures
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Clovis Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Clovis Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Clovis Oncology Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Clovis Oncology Inc, Medical Devices Deals, 2012 to YTD 2018 10
Clovis Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Clovis Oncology Enters into Agreement with Immunomedics 12
Bristol-Myers Squibb and Clovis Oncology Enter into Agreement 13
Clovis Oncology Enters into Agreement with Strata Oncology 14
Clovis Oncology Enters into Agreement with Genentech 15
Clovis Oncology Enters Into Co-Development Agreement With Array BioPharma 16
Clovis Oncology Enters into Licensing Agreement with Gatekeeper Pharma 17
Clovis Oncology Enters into Licensing Agreement with AstraZeneca 18
Clovis Oncology Raises USD100 Million in Public Offering of Shares 19
Clovis Oncology Raises USD342.4 Million in Public Offering of Shares 21
Clovis Oncology Raises USD235.75 million in Public Offering Of Shares 23
Clovis Oncology Raises USD316 Million in Public Offering of Shares 25
Clovis Oncology Completes Public Offering Of Shares For USD 262 Million 27
Clovis Oncology Completes Public Offering Of Common Stock For USD 75 Million 29
Clovis Oncology Raises USD300 Million in Public Offering of Notes Due 2025 31
Clovis Oncology Completes Private Placement of Notes Due 2021 for USD287.5 Million 32
Clovis Oncology Acquires EOS For USD 420 Million 33
Clovis Oncology Inc, Key Competitors 35
Clovis Oncology Inc, Key Employees 36
Clovis Oncology Inc, Other Locations 37
Clovis Oncology Inc, Subsidiaries 37
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Clovis Oncology Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
: +91 99224 42855 
Related Reports
Page 157 | 
June 2021
Page 130 | December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020